Scientific Experts


Lyle Arnold, Ph.D. | Senior Vice-President of Research & Development, Chief Scientific Officer

Dr. Arnold is a biotechnology executive, entrepreneur, and developer of innovative technologies covering therapeutics, molecular diagnostics, and genomics. Dr. Arnold recently founded Aegea Biotechnologies to acquire, develop, and commercialize, next generation nucleic acid technologies. Dr. Arnold also serves on the board of directors of Asuragen, a rapidly emerging biotechnology company in Austin, Texas as well as on the board of Aegea. Previously he was VP, Research at Gen-Probe from September 2003 to October 2009.

He has also held senior scientific and management positions at Molecular Biosystems (co-founder), Genta, Synteni, Incyte Genomics, and Oasis Biosciences (co-founder), where he was President and Chief Scientific Officer from October 2001 to September 2003. In addition, Dr. Arnold was a faculty member in the UCSD School of Medicine and a member of the UCSD Cancer Center. Dr. Arnold is an inventor or co-inventor on 36 issued U.S. patents and more than 140 issued and pending patents worldwide. He is the principal inventor of the chemiluminescent Hybridization Protection Assay (HPA) and associated technologies core to Gen-Probe assays that have generated more than $5B in product revenue. In addition, he has authored more than 50 scientific publications.

He received a B.S. in Chemistry from the University of California at Los Angeles and a Ph.D. in Chemistry/Biochemistry from the University of California at San Diego.


Veena Singh, MD | Senior Vice President and Senior Medical Director

Dr. Singh brings years of laboratory diagnostics experience and a deep personal interest in blood-based biomarker testing. Prior to joining Biocept, Dr. Singh led the clinical laboratory team as the Medical Director at the molecular oncology diagnostics company bioTheranostics Inc. Her expertise in validating and launching assays in a CLIA lab setting, along with extensive knowledge of developmental stage biomarkers, serve as a major catalyst for Biocept’s continuing expansion of its offerings.

During Dr. Singh’s tenure at bioTheranostics Inc., the clinical laboratory’s test menu underwent significant expansion to incorporate assays in solid tumor molecular analysis utilizing multiple methodologies and platforms including Next-Generation Sequencing, RT-PCR, IHC and FISH. In addition, she brings a wealth of experience in the fields of regulatory agency compliance and reimbursement (FDA, IVDMIA and Companion Diagnostics).

Dr. Singh completed a Molecular Genetic Pathology fellowship at Cedars-Sinai Medical Center in Los Angeles and an Anatomic and Clinical pathology residency at the University of California, San Diego. Dr. Singh is board certified in Anatomic and Clinical Pathology and Molecular Genetic Pathology. She received her medical degree from the University of Transkei in South Africa and is a Fellow of the College of American Pathologists and the American College of Medical Genetics.